Vaccine Manufacturer Perception Rankings 2025: Which Companies Have HCP Trust After HHS Mandate Removal?

The vaccine market fundamentally changed on January 5, 2026. The HHS decision to reclassify six major vaccines—including Influenza, COVID-19, Hepatitis A/B, Meningitis, and Rotavirus—as "Shared Clinical Decision-Making" (SCDM) eliminated guaranteed volume for a significant portion of the market.

Without federal mandates, manufacturer reputation and healthcare provider (HCP) advocacy are now the only forces sustaining voluntary uptake.

Q4 2025 Vaccine Perception Rankings

ZoomRx surveyed 58 US-based HCPs in December 2025, evaluating 14 vaccine manufacturers across five dimensions: Innovation, Patient Centricity, Reputation, HCP Centricity, and Promotions.

Top 5 Manufacturer Rankings (Out of 100)

1. Pfizer: 83 — Dominant across innovation, patient centricity, and engagement
2. Merck: 48 — Dependable but lacks differentiation
3. Moderna: 37 — COVID-era credibility must evolve beyond pandemic narrative
4. GSK: 34 — Rebounding with improved HCP engagement
5. AstraZeneca: 27 — High-touch partnership model driving gains

Three Critical Trends for Vaccines in 2026

1. Innovation redefined: "Novel science" is no longer enough. Manufacturers must equip HCPs with "personalizable value" arguments to convince skeptical parents.
2. Advocacy as survival: In an optional market, HCPs only recommend vaccines from manufacturers they deeply trust. Low advocacy scores mean disappearing from clinical conversations entirely.
3. The Essential vs. Optional split: Mandated vaccines (DTaP, Polio, MMR) retain guaranteed volume, but optional vaccines require fundamentally different commercial strategies.
   

What's Inside the Full Report:

• Detailed perception scores for all 14 vaccine manufacturers
• HCP verbatims explaining what drives trust
• Net Promoter Score trends and strategic recommendations
• Complete methodology and sample details